First author, year | Collaboration | Sample size with SVR12 data | Proportion of genotype 1a (%) | In combination with ribavirin† | Age (years) | Male, N (%) | Advanced fibrosis, N (%) | Median or mean time to post-LT treatment in months or years | Proportion with tacrolimus use (%) |
---|---|---|---|---|---|---|---|---|---|
Pungpapong, 201513 | Multicentre | 105 | 60 | Mix | 61.6±6 | 77 (76) | 37 (37) | 32 (2–317) months | 91 |
Gutierrez, 201516 | Single centre | 61 | 57 | Without | 60.2±9.3 | 22 (59) | 14 (38) | 5.4 years (1.9–8.4) | 80 |
Gordon, 201417 | Single centre | 15 | – | Without | – | – | 1 (6) | – | 82 |
Suliman, 201411 | Single centre | 8 | 90 | Without | 62.5 | 6 (60) | – | – | – |
Lutchman, 201415 | Single centre | 31 | 64 | Without | 61.2±7.1 | 43 (81) | 11 (33) | 47.0 (1.4–1278.3) months | 96 |
Nair, 201414 | Single centre | 27 | 70 | With | 56±5 | 28 (61) | 19 (41) | 0.9±1.6 years | 78 |
Ripper, 201412 | Single centre | 23 | 60 | Mix | 60.9 | 21 (84) | 7 (28) | 32.3 (2–215.2) months | 76 |
Crittenden, 201419 | Single centre | 18 | 74 | Mix | – | – | – | – | – |
Ford, 201418 | Single centre | 37 | 68 | Mix | 57 | 27 (73) | 8 (22) | – | 62 |
*Proportions and mean±SD were provided/abstracted from the total number of patients available from each study.
†Classification of studies that included patients: with ribavirin, without ribavirin, or a mix of patients with and without ribavirin.
LT, liver transplantation; SVR, sustained virological response.